capreomycin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, produced by Streptomyces strains 3063 11003-38-6

Description:

MoleculeDescription

Synonyms:

  • capreomycin
  • capastat
  • capostatin
  • capreomicin
  • capromycin
  • capreomycin sulfate
  • capreomycine
  • capreomycine sulfate
Cyclic peptide antibiotic similar to VIOMYCIN. It is produced by Streptomyces capreolus.
  • Molecular weight: 1321.44
  • Formula: C50H88N28O15
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA: 378.42
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
1 g P

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 26.61 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
June 2, 1971 FDA AKORN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 112.74 69.40 33 488 72423 90555503
Drug resistance 109.92 69.40 27 494 30422 90597504
Hepatitis B 87.04 69.40 16 505 4503 90623423

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 96.28 40.99 31 446 47914 42572944
Drug resistance 89.02 40.99 27 450 34221 42586637
Neuropathy peripheral 50.83 40.99 24 453 101829 42519029
Hepatotoxicity 49.18 40.99 16 461 25151 42595707

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Electrocardiogram QT prolonged 187.93 43.90 60 963 108900 110479376
Drug resistance 157.10 43.90 45 978 56329 110531947
Neuropathy peripheral 73.94 43.90 35 988 179242 110409034
Hepatitis B 67.30 43.90 16 1007 9596 110578680
Optic neuropathy 67.11 43.90 14 1009 4644 110583632
Hepatotoxicity 58.56 43.90 22 1001 63378 110524898

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J04AB30 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIMYCOBACTERIALS
DRUGS FOR TREATMENT OF TUBERCULOSIS
Antibiotics
FDA EPC N0000175483 Antimycobacterial
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000904 Antibiotics, Antitubercular
MeSH PA D000995 Antitubercular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D011500 Protein Synthesis Inhibitors

Related Drugs by ATC class:

J04AB Antibiotics 6 drugs
cycloserineenviomycinrifabutinrifampicinrifamycinrifapentine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Acute tuberculosis indication 25629007
Pulmonary tuberculosis indication 154283005 DOID:2957
Hearing loss contraindication 15188001
Dehydration contraindication 34095006
Hypokalemia contraindication 43339004
Neuromuscular block, function contraindication 55394004
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Disorder of the 8th Cranial Nerve contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019652 VUID
N0000178639 NUI
D00135 KEGG_DRUG
4017459 VANDF
4019652 VANDF
C0262964 UMLSCUI
CHEBI:3371 CHEBI
CHEMBL2221250 ChEMBL_ID
CHEMBL2218913 ChEMBL_ID
D002207 MESH_DESCRIPTOR_UI
DB00314 DRUGBANK_ID
1145 INN_ID
1405-37-4 SECONDARY_CAS_RN
232HYX66HC UNII
3000502 PUBCHEM_CID
1987 RXNORM
4345 MMSL
d01103 MMSL
002787 NDDF
004901 NDDF
14170004 SNOMEDCT_US
387081001 SNOMEDCT_US
85580008 SNOMEDCT_US

Pharmaceutical products:

None